{
    "organizations": [],
    "uuid": "693bf239fb0020a913048a375a8772d24d7142f2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dicerna-reports-qtrly-loss-per-sha/brief-dicerna-reports-qtrly-loss-per-share-of-0-90-idUSASB0C9JI",
    "ord_in_thread": 0,
    "title": "BRIEF-Dicerna Reports Qtrly Loss Per Share Of $0.90",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Dicerna Pharmaceuticals Inc:\n* DICERNA REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE\n* DICERNA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.90\n* DICERNA PHARMACEUTICALS - BELIEVES IT HAS SUFFICIENT CASH TO FUND EXECUTION OF CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-09T05:22:00.000+02:00",
    "crawled": "2018-03-09T14:16:45.021+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "dicerna",
        "pharmaceutical",
        "inc",
        "dicerna",
        "report",
        "fourth",
        "quarter",
        "year",
        "end",
        "financial",
        "operating",
        "result",
        "provides",
        "corporate",
        "update",
        "dicerna",
        "pharmaceutical",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "dicerna",
        "pharmaceutical",
        "belief",
        "sufficient",
        "cash",
        "fund",
        "execution",
        "current",
        "clinical",
        "operating",
        "plan",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}